⌘K

21:51:29·69d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Aridis Pharmaceuticals Inc.

ByQuantisnow·Wall Street's wire, on your screen.

ARDS· Aridis Pharmaceuticals Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

ARDS
Aridis Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Jul 20UpdateHC Wainwright & Co.$19.00

Related

PR494d
Aridis Provides Corporate Update
13D/G529d
Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.
INSIDER668d
SEC Form 4 filed by Director Hamilton John F
INSIDER668d
SEC Form 4 filed by Director Windham-Bannister Susan Richards
INSIDER668d
SEC Form 4 filed by Chief Medical Officer Jafri Hasan
INSIDER668d
Director Patzer Eric bought $50,000 worth of Common stock purchase (714,286 units at $0.07), increasing direct ownership by 419% to 884,600 units (SEC Form 4)
INSIDER668d
CEO Truong Vu bought $50,000 worth of Common stock purchase (714,286 units at $0.07), increasing direct ownership by 108% to 1,378,639 units (SEC Form 4)
SEC669d
Aridis Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities